Onconova Therapeutics (NASDAQ: ONTX) Lowered to Hold at Zacks Investment Research

Onconova (NASDAQ: ONTX) was devalued by  Zacks Research  from a “purchase” ranking to a “hold” ranking in a research note released to financiers on Thursday, Zacks.com reports.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical business. It concentrates on discovering and also establishing small molecule medicine prospects to deal with cancer cells. The Business‘s items under various phases of advancement consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 as well as Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Numerous various other equities research analysts also recently talked about the firm. Noble Financial editioned a “buy” score as well as provided a $11.00 price objective on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their rate target on Onconova Therapeutics from $29.00 to $12.00 and established a “buy” score on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and a twelve month high of $28.95. The business has a 50 day moving typical price of $2.90 as well as a two-hundred day relocating average rate of $4.16. The firm has a market cap of $46.76 million, a P/E proportion of -1.82 as well as a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly profits results on Thursday, November 11th. The biopharmaceutical business reported ($ 0.22) profits per share for the quarter, covering analysts’ consensus price quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an unfavorable return on equity of 59.78% and also an adverse net margin of 8,294.27%. The company had revenue of $0.06 million throughout the quarter, compared to the agreement price quote of $0.06 million. During the same quarter in the previous year, the firm uploaded ($ 0.45) EPS. En masse, research analysts forecast that Onconova Therapeutics will certainly publish -1.18 EPS for the present year.

A variety of hedge funds have actually recently bought and sold shares of ONTX. GSA Capital Partners LLP acquired a new placement in Onconova Therapeutics throughout the third quarter worth $922,000. Hudson Bay Resources Administration LP bought a new placement in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC bought a brand-new placement in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC acquired a new position in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Lastly, Dimensional Fund Advisors LP bought a new setting in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds as well as various other institutional capitalists have 13.36% of the company’s stock.

Concerning Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical firm, which participates in the identification and growth of oncology therapeutics. It concentrates on uncovering and also developing tiny molecule medication prospects to deal with cancer. The firm was founded by Ramesh Kumar as well as E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA

. Get a complimentary duplicate of the Zacks research report on Onconova Therapeutics (ONTX).

For additional information regarding research offerings from Zacks Investment Research, check out Zacks.com.

This instantaneous information alert was generated by narrative science innovation and also economic information from Market in order to supply viewers with the fastest and also most exact coverage. This story was examined by Market’s editorial group prior to publication. 



Prior to you consider Onconova Therapeutics, you’ll wish to hear this.

Market keeps an eye on Wall Street’s top-rated as well as best doing research analysts and also the stocks they suggest to their customers daily. Market has actually recognized the 5 stocks that top experts are quietly whispering to their customers to buy currently prior to the broader market catches on … and also Onconova Therapeutics had not been on the listing.

While Onconova Therapeutics currently has a “Buy” rating among experts, premier analysts believe these five stocks are better buys.